Relia Tech/Rat Anti-Mouse Trk-C/100 µg/103-M198
市场价：
¥5500.00
美元价：
3300.00
产品分类：
单克隆抗体
公司分类：
monoclonal_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | 103-M198 |
| Size | 100 µg |
| Price | 275 € |
| Category | Monoclonal Antibody |
| Clone Nr. | (#6G17) |
| Isotype | IgG1 |
| Species Reactivity | Mouse |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml. |
| Stability and Storage | Lyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity. |
| Preparation | This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a rat) immunized with purified recombinant mouse TrkC extracellular domain. |
| Antigen | recombinant Mouse Trk-C extracellular domain |
| Application | WB |
| Synonyms | Ntrk3; TrkC; AW125844; Ntrk3_tv3 |
| Description | The neurotrophins, including NGF, BDNF, NT3 and NT4/5, constitute a group of structurally related, secreted proteins that play an important role in the development and function of the nervous system. The biological activities of the neurotrophins are mediated by binding to and activating two unrelated receptor types: the p75 neurotrophin receptor (p75NTR) and the Trk family of receptor tyrosine kinases. p75NTR is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and has been designated TNFRSF16. It binds all neurotrophins with low affinity to transduce cellular signaling pathways that synergize or antagonize those activated by the Trk receptors. Three Trk family proteins, TrkA, TrkB, and TrkC, exhibiting different ligand specificities, have been identified. TrkA binds NGF and NT3, TrkB binds BDNF, NT3 and NT4/ 5, and TrkC only binds NT3. All Trk family proteins share a conserved, complex subdomain organization consisting of a signal peptide, two cysteinerich domains, a cluster of three leucine-rich motifs, and two immunoglobulinlike domains in the extracellular region, as well as an intracellular region that contains the tyrosine kinase domain. Natural splice variants of the different Trks, lacking the first cysteine-rich domain, the first and second or all three of the leucine-rich motifs, or the tyrosine kinase domain, have been described. At the protein sequence level, Trks are highly conserved between species with the extracellular domains of human and mouse TrkC showing 94% amino acid sequence identity. The proteins also exhibit cross-species activity. The primary location of TrkC expression is in the nervous system and, specifically, in regions of the CNS. Low level TrkC expression has also been observed in a wide variety of tissues outside the nervous system. |
| Uniprot ID | Q6VNS1 |
| Protein RefSeq | NP_032772 |
| mRNA RefSeq | NM_008746 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
